MYGN 250117 17.00P (MYGN250117P17000) Stock Options, News & Quotes

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

MYGN250117P17000

Watchlist

0.00
0.000.00%

15min DelayClose Jan 17 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

Express News | Stephens & Co. Reiterates Equal-Weight on Myriad Genetics, Maintains $20 Price Target
BenzingaJan 16 10:28 ET
Myriad Genetics Analyst Ratings
BenzingaJan 16 10:27 ET · Ratings
BofA Securities Maintains Myriad Genetics(MYGN.US) With Sell Rating, Maintains Target Price $13
Moomoo NewsJan 15 20:32 ET · Ratings
Myriad Genetics: Sell Rating Maintained Amid Mixed Financial Outlook and Limited Catalysts
TipRanksJan 15 20:18 ET · Ratings
TD Cowen Maintains Myriad Genetics(MYGN.US) With Hold Rating, Cuts Target Price to $17
Moomoo NewsJan 15 10:31 ET · Ratings
Myriad Genetics Expects Higher Q4 Revenue, Provides 2025 Guidance
MT NewswiresJan 15 09:53 ET

Comments

905745367

Dec 6, 2024 09:01

$Myriad Genetics (MYGN.US)$ what happen to this stock?

Trytosaveabit

Mar 20, 2024 15:22

Bad sign when a patent granted gets zero attention!

$Myriad Genetics (MYGN.US)$ Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device 16 MINUTES AGO, 4:05 PM EDT VIA GLOBENEWSWIRE

Moomoo AI

Feb 1, 2024 08:31

The acquisition is expected to enable Myriad to more effectively scale and grow its tumor profiling offerings to complement its oncology portfolio of hereditary cancer and companion diagnostic testing options.

Press Release: Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory From Intermountain Precision Genomics

Moomoo AI

Jan 30, 2024 16:00

Dr. Daneker's leadership is expected to drive innovation, growth, and development of the company's oncology portfolio, including expansions into liquid biopsy and minimal residual disease testing. His experience and track record are anticipated to boost the company's strategy with health systems and large oncology practices.

Press Release: Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology

Moomoo AI

Jan 18, 2024 17:37

The acquisition is set to spur innovation, growth, and further development of Myriad's oncology portfolio. It will also enhance the scaling and growth of their tumor profiling and liquid biopsy tests, including operational efficiencies, reimbursement benefits and new clinical development opportunities.

Press Release: Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory From Intermountain Precision Genomics